ClinicalTrials.gg
TerminatedNCT06984328Updated Sep 30, 2026Results posted

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

A Phase 2 interventional study of Acasunlimab and Pembrolizumab in Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID) and Metastatic Cutaneous Melanoma (Stage IV), sponsored by Genmab. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Genmab · Phase 2, Interventional, and Treatment

Why this study was terminated
Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.
Updated Sep 30, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
1,675th of 1,749
1 · median 37
Started
2025
with 61 others
Phase 2
612 of 2,049
46 open now
Registered
1,970th of 2,049
by date

Among the 2,049 studies in Melanoma with a site in United States, this one is the 1,675th largest by enrollment of the 1,749 interventional ones that give a count, is one of 62 that started in 2025, is one of 612 in phase 2, and was the 1,970th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

238 more — sign in →

All 243 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,049 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. All participants will receive active drugs; no one will be given a placebo.

The trial duration will be approximately 15 months for each participant, including a 28-day screening period and estimated 4-month treatment and 10-month follow-up periods; however, the duration of the treatment and follow-up periods may vary for each participant.

Participants will have regular check-ups while on treatment, with visits every week initially, and then every 3 weeks later in the trial.

Read the detailed description

This is a Phase 2, randomized, open-label, multicenter trial evaluating the efficacy and safety of acasunlimab as monotherapy and in combination with pembrolizumab in adult participants with relapsed/refractory, unresectable locally advanced or metastatic cutaneous melanoma who progressed on or after prior checkpoint inhibitor (CPI)-containing therapy. Participants will be randomized in a 1:1 ratio to receive acasunlimab and pembrolizumab or acasunlimab alone.

Eligible participants must have received a minimum of 2 cycles of an approved anti-programmed cell death protein 1 (PD-1) containing therapy. Participants whose tumor harbors a B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600 mutation are eligible for the trial if they have received a BRAF-directed therapy (with or without a mitogen-activated protein kinase [MEK] inhibitor) prior to enrollment in the trial, unless the investigator has deemed a BRAF-directed therapy not clinically indicated. BRAF V600 mutational status must be determined by local assessment and documented.

03

Conditions studied

  • Cutaneous Melanoma
  • Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)
  • Metastatic Cutaneous Melanoma (Stage IV)

Keywords

  • Melanoma
  • Cutaneous Melanoma
  • Metastatic Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants ≥ 18 years of age with or cytologically confirmed diagnosis of , locally advanced unresectable (Stage IIIB, IIIC, or IIID) or (Stage IV) cutaneous melanoma, per American Joint Committee on Cancer (8th edition) staging.
  • Participant must have radiographic progression based on v1.1 on or following ≥ 1 prior systemic therapy, according to local and international guidelines, including a programmed cell death protein 1 blocking antibody () treatment or combination treatment containing an anti-PD-1.
  • Participant must have received a minimum of 2 cycles of an approved anti-PD-1 as monotherapy or a combination therapy containing an anti-PD-1.
  • and/or adjuvant systemic therapy count as the of prior systemic therapy if there is documented disease progression ≤ 6 months after completion of therapy.
  • Participants with a BRAF V600 mutation should have received prior BRAF-directed therapy (with or without a MEK inhibitor) prior to enrollment in the trial, unless deemed not clinically indicated by the Investigator due to concurrent medical condition or prior toxicity.
  • Participant has an performance status of 0 or 1 within 7 days prior to Cycle 1 Day 1.

Key Exclusion Criteria:

  • Participants with non-cutaneous or acral melanoma.
  • Participants with newly identified or known unstable or symptomatic central nervous system metastases or history of carcinomatous meningitis.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Acasunlimab in Combination with Pembrolizumab

    Participants with relapsed/refractory, unresectable locally advanced or metastatic cutaneous melanoma that progressed on/after prior CPI(s) will receive acasunlimab once every 6 weeks (Q6W) in combination with pembrolizumab Q6W.

    Biological: Acasunlimab · Biological: Pembrolizumab

  • Experimental
    Acasunlimab

    Participants with relapsed/refractory, unresectable locally advanced or metastatic cutaneous melanoma that progressed on/after prior CPI(s) will receive acasunlimab Q6W.

    Biological: Acasunlimab

Interventions

  • BiologicalAcasunlimab

    Intravenous (IV) infusion

    Also known as: GEN1046, DuoBody®-PD-L1×4-1BB

  • BiologicalPembrolizumab

    IV infusion

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a confirmed response of complete response (CR) or partial response (PR) assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 9 months

Secondary outcomes

  1. Time to Response (TTR)

    TTR per RECIST v1.1 as assessed by the investigator was defined as the time from the date of first administration of trial drug to the first documented response of either CR or PR.

    Time frame: Up to approximately 9 months

  2. Duration of Response (DOR)

    DOR per RECIST v1.1 as assessed by the investigator was defined as the time from first documentation of objective response (PR or CR) that was subsequently confirmed, to the first documentation of disease progression or death due to any cause, whichever came first.

    Time frame: Up to approximately 9 months

  3. Progression-free Survival (PFS)

    PFS was defined as the time from the date of first administration of trial drug to the date of the first documented progression or death due to any cause, whichever occurred first.

    Time frame: Up to approximately 9 months

  4. Overall Survival (OS)

    OS was defined as the time from date of first administration of trial drug to date of death due to any cause.

    Time frame: Up to approximately 9 months

  5. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical trial participant, associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A TEAE was any AE that started after or worsened after drug administration.

    Time frame: Up to approximately 9 months

  6. Time to Treatment Discontinuation Due to AEs

    Time frame: Up to approximately 9 months

07

Results

Posted Sep 30, 2026
Limitations and caveats
This trial was terminated after one participant was enrolled for strategic portfolio reasons. Genmab decided to discontinue further clinical development of acasunlimab following a strategic portfolio prioritization. The decision was not related to safety concerns.

Participant flow

Participant flow — Overall Study
MilestoneArm B: Acasunlimab
Started0
Completed0
Not completed0

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with a confirmed response of complete response (CR) or partial response (PR) assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to approximately 9 months
Reported as:
Number · percentage of participants

No measurements were reported for this outcome.

SecondaryTime to Response (TTR)

TTR per RECIST v1.1 as assessed by the investigator was defined as the time from the date of first administration of trial drug to the first documented response of either CR or PR.

Time frame:
Up to approximately 9 months
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryDuration of Response (DOR)

DOR per RECIST v1.1 as assessed by the investigator was defined as the time from first documentation of objective response (PR or CR) that was subsequently confirmed, to the first documentation of disease progression or death due to any cause, whichever came first.

Time frame:
Up to approximately 9 months
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryProgression-free Survival (PFS)

PFS was defined as the time from the date of first administration of trial drug to the date of the first documented progression or death due to any cause, whichever occurred first.

Time frame:
Up to approximately 9 months
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

OS was defined as the time from date of first administration of trial drug to date of death due to any cause.

Time frame:
Up to approximately 9 months
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical trial participant, associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A TEAE was any AE that started after or worsened after drug administration.

Time frame:
Up to approximately 9 months
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

SecondaryTime to Treatment Discontinuation Due to AEs
Time frame:
Up to approximately 9 months
Reported as:
Mean · days

No measurements were reported for this outcome.

Adverse events

Collected over Up to approximately 9 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm B: Acasunlimab———

Baseline characteristics

The study participant did not consent to publishing his/her individual data. As there was only one participant in this trial, no data are reported in order to protect and maintain participant privacy/confidentiality.

Age, Continuous
Age, ContinuousArm B: Acasunlimab
Sex: Female, Male
Sex: Female, Male(Participants)Arm B: Acasunlimab
Female—
Male—
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm B: Acasunlimab
Hispanic or Latino—
Not Hispanic or Latino—
Unknown or Not Reported—
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm B: Acasunlimab
American Indian or Alaska Native—
Asian—
Native Hawaiian or Other Pacific Islander—
Black or African American—
White—
More than one race—
Unknown or Not Reported—
08

Study locations

2 sites
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Pan American Center for Oncology Trials, LLC
    San Juan, Puerto Rico 00909, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in May 2026, 9 months.

Results were first posted in Sep 2026, 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
May 22, 2025
StartActual
Jul 25, 2025
Primary completionActual
May 15, 2026
CompletionActual
May 15, 2026
Results first posted
Sep 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 30, 2026
Sites
1 site added, 1 site removed
Show site
  • Pan American Center for Oncology Trials, LLC · San Juan, Puerto Rico
Show 1 removed
  • Pan American Center for Oncology Trials, LLC · San Juan, Puerto Rico
Sep 30, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameObjective Response Rate (ORR)Up to approximately 12 months → Up to approximately 9 months
  • DescriptionObjective Response Rate (ORR): how it is measured was reworded
Sep 30, 2026
Documents
Secondary outcomes
2 edited, 4 time frame changed, 4 description edited
What changed in the outcomes
  • EditedNumber of Participants withWith Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 15 months → Up to approximately 9 months
  • EditedTime to Treatment Discontinuation Due to Adverse Events (AEs)Time frame: Up to approximately 15 months → Up to approximately 9 months
  • Time frameTime to Response (TTR)Up to approximately 15 months → Up to approximately 9 months
  • Time frameDuration of Response (DOR)Up to approximately 15 months → Up to approximately 9 months
  • Time frameProgression-free Survival (PFS)Up to approximately 15 months → Up to approximately 9 months
  • Time frameOverall Survival (OS)Up to approximately 15 months → Up to approximately 9 months
  • DescriptionDuration of Response (DOR): how it is measured was reworded
  • DescriptionOverall Survival (OS): how it is measured was reworded
  • DescriptionProgression-free Survival (PFS): how it is measured was reworded
  • DescriptionTime to Response (TTR): how it is measured was reworded
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Pan American Center for Oncology Trials, LLC · San Juan, Puerto Rico
    Show 1 removed
    • Pan American Center for Oncology Trials, LLC · San Juan, Puerto Rico
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameObjective Response Rate (ORR)Up to approximately 12 months → Up to approximately 9 months
    • DescriptionObjective Response Rate (ORR): how it is measured was reworded
    Secondary outcomes 2 edited, 4 time frame changed, 4 description edited
    What changed in the outcomes
    • EditedNumber of Participants withWith Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 15 months → Up to approximately 9 months
    • EditedTime to Treatment Discontinuation Due to Adverse Events (AEs)Time frame: Up to approximately 15 months → Up to approximately 9 months
    • Time frameTime to Response (TTR)Up to approximately 15 months → Up to approximately 9 months
    • Time frameDuration of Response (DOR)Up to approximately 15 months → Up to approximately 9 months
    • Time frameProgression-free Survival (PFS)Up to approximately 15 months → Up to approximately 9 months
    • Time frameOverall Survival (OS)Up to approximately 15 months → Up to approximately 9 months
    • DescriptionDuration of Response (DOR): how it is measured was reworded
    • DescriptionOverall Survival (OS): how it is measured was reworded
    • DescriptionProgression-free Survival (PFS): how it is measured was reworded
    • DescriptionTime to Response (TTR): how it is measured was reworded
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06984328
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
May 22, 2025
Start date
Jul 25, 2025
Primary completion
May 15, 2026
Completion
May 15, 2026
Results posted
Sep 30, 2026
Last update
Sep 30, 2026

Study contacts

Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acasunlimab

Start the discussion